Natera (NTRA) Set to Release Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2812) per share and revenue of $707.54 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same period last year, the business posted ($0.74) earnings per share. On average, analysts expect Natera to post ($1.14) EPS for the current fiscal year and ($0.10) EPS for the next fiscal year.

Natera Trading Up 3.6%

Natera stock traded up $13.61 during mid-day trading on Tuesday, reaching $392.52. The company’s stock had a trading volume of 1,351,737 shares, compared to its average volume of 1,408,926. Natera has a twelve month low of $181.00 and a twelve month high of $437.41. The business has a 50 day moving average price of $378.00 and a 200-day moving average price of $267.14. The firm has a market cap of $56.58 billion, a price-to-earnings ratio of -287.64 and a beta of 1.55.

Insider Activity

In other Natera news, insider John Fesko sold 898 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total transaction of $382,853.32. Following the completion of the transaction, the insider directly owned 195,578 shares of the company’s stock, valued at $83,382,724.52. The trade was a 0.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of the company’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30. Following the completion of the transaction, the chief financial officer owned 46,574 shares of the company’s stock, valued at approximately $19,819,565.70. This trade represents a 3.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 45,256 shares of company stock valued at $16,455,344. 5.05% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price target on shares of Natera from $360.00 to $460.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Roth Capital began coverage on shares of Natera in a research report on Thursday, October 22nd. They set a “buy” rating and a $475.00 price objective for the company. Rothschild & Co Redburn initiated coverage on shares of Natera in a research note on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective on the stock. Stephens raised their target price on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $394.31.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.